Compare iShares MBS ETF (MBB) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Moderna, Inc. — how do they compare? iShares MBS ETF trades at $93.37, while Moderna, Inc. trades at $59.69 (market cap $23.60B). The key difference: Moderna, Inc. is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| MBB | MRNA | |
|---|---|---|
52-Week High | $96.91 | $81.80 |
52-Week Low | $92.92 | $22.36 |
Market Cap | — | $23.60B |
Sector | — | Health |
Enterprise Value | — | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $93.57, down 0.22% on the day, with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings and has upcoming dividend payments. Recent news highlights institutional activity, including Comerica Bank reducing its stake while Concurrent Investment Advisors and Aureum Wealth increased positions in Q4 2026.
The outlook remains cautious due to bearish technical trends and mixed institutional sentiment. Risks include interest rate sensitivity impacting mortgage-backed securities. Opportunities lie in steady dividend income, but investors should monitor Federal Reserve policy shifts for potential volatility in the MBS market.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
